EMA Withdrawn: Pioglitazone Teva (pioglitazone hydrochloride) — Teva B.V.

View source ↗

Summary

Pioglitazone Teva (pioglitazone hydrochloride) has been withdrawn from the European market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Pioglitazone Teva (pioglitazone hydrochloride)

Snippet

Status: Withdrawn. Therapeutic area: Diabetes Mellitus, Type 2. MAH: Teva B.V.. Decision date: 04/11/2021